Document text
Principal Investigator: Donald YM Leung
Organization: NATIONAL JEWISH HEALTH
Fiscal Year: 2024
Award: $4,354,533
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY/ABSTRACT
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the general population. AD is
associated with defective skin barrier function, microbial dysbiosis, as well as various cutaneous immune
abnormalities including type 2 inflammation and decreased cutaneous host defense. These abnormalities
translate into multiple phenotypes and endotypes that are not fully defined and therefore, effective targeted
therapies, beyond type 2 immune blockade, to reverse these various subsets of AD are lacking. Beyond its
effects on cutaneous defense, AD is associated with systemic inflammation and appears to be the first step in
the development of other atopic conditions including food allergy and asthma.
This grant application is being submitted in response to RFA-AI-19-014, Atopic Dermatitis Research
Network-Leadership Center (ADRN-LC). The goal of this proposal is to create an ADRN-LC which will
provide the overall scientific strategy and organizational structure to the ADRN and will interact closely with
the ADRN Clinical Research Centers (ADRN-CRCs), to support the conduct of multi-site clinical studies and
trials that will elucidate mechanisms of skin barrier dysfunction and cutaneous immune responses in
atopic dermatitis (AD).
The central hypothesis in this application is that different phenotypes and endotypes of AD are
associated with distinct defects in their skin barrier, microbiome, and skin immune responses which can
be characterized by novel approaches to skin sampling and open up avenues for paradigm shifting
therapeutic interventions to benefit patients with severe persistent AD. We will achieve our objectives
with the following Aims:
· Specific Aim 1: To establish an Administrative and Clinical Research Operations Leadership
Center that will be responsible for implementation, coordination, and funding of clinical trials and
studies for the ADRN-LC in research areas evaluating mechanism and treatment of AD.
· Specific Aim 2: To develop a Network-wide multi-center ADRN clinical trial to evaluate the long-
term effects of targeted microbiome transplantation on clinical outcomes in AD as well as epithelial
barrier function, microbial dysbiosis, and cutaneous immunity.
· Specific Aim 3: To design a Network-wide ADRN one-year observational study to assess the
stability of AD phenotypes/endotypes using a Network correlation analysis of transcriptomics
(conventional and single cell RNA sequencing), skin tape proteomics, lipidomics, and microbiome
over time in subjects with persistent mild vs. persistent severe AD and assessment of therapeutic
responses to topical corticosteroids and Dupilumab.
· Specific Aim 4: To carry out a Network-wide multi-center ADRN clinical trial to examine the effects
of targeted IL-1 blockade on the clinical outcome, skin microbiome, epithelial skin barrier, and
cutaneous immune response in AD patients who have an inadequate response to IL-4/IL-13 blockade
using Dupilumab therapy.
Accomplishment of these Specific Aims will contribute to novel and important advances in our
understanding of mechanisms of host skin defense and paradigm-shifting treatments of AD. The
establishment of this ADRN-LC will also provide budgetary and scientific resources for the Systems
Biology of Early Atopy Birth Cohort study that is under development by the Consortium for Food Allergy
Research (CoFAR).
Terms: <Allergic to food><Allergy><Allergy to food><Applications Grants><Area><Asthma><Atopic Allergy><Atopic Dermatitis><Atopic Eczema><Atopic Neurodermatitis><B cell growth factor><B-Cell Differentiation Factor-1><B-Cell Growth Factor-1><B-Cell Growth Factor-I><B-Cell Proliferating Factor><B-Cell Stimulating Factor><B-Cell Stimulating Factor-1><B-Cell Stimulation Factor-1><B-Cell Stimulatory Factor-1><BCDF-1><BCGF><BCGF-1><BCSF 1><BSF-1><BSF1><Bacterial Infections><Binetrakin><Biological><Birth><Bronchial Asthma><Clinical><Clinical Research><Clinical Study><Clinical Trials><Cohort Studies><Collaborations><Communication><Concurrent Studies><Cutaneous><Cutaneous Disorder><Data Coordinating Center><Data Coordination Center><Defect><Dermatoses><Development><Disseminated Neurodermatitis><Dysfunction><Ensure><Epithelium><Food Allergy><Food Hypersensitivity><Functional disorder><Funding><General Population><General Public><Goals><Grant><Grant Proposals><Health><Hospital Admission><Hospitalization><Host Defense><Hypersensitivity><IL-1><IL-13><IL-4><IL1><IL13><IL4 Protein><Immune><Immune response><Immunes><Immunity><Immunological response><Impairment><Inflammation><Infrastructure><Interleukin I><Interleukin-1><Interleukin-13><Interleukin-4><Interleukin-4 Precursor><Intervention><Intervention Strategies><Intervention Studies><Investigators><Jewish><Judaism><Leadership><Long-Term Effects><Longterm Effects><Lymphocyte Stimulatory Factor 1><Lymphocyte-Stimulating Hormone><MCGF-2><Macrophage Cell Factor><Mast Cell Growth Factor-2><Morbidity><Morbidity - disease rate><Multi-center clinical study><Multi-site clinical study><Multicenter clinical study><Multisite clinical study><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Observation research><Observation study><Observational Study><Observational research><Operations Research><Organization Charts><Outcome><Parturition><Pathway interactions><Patients><Performance><Phenotype><Physiopathology><Proteomics><Protocol><Protocols documentation><QOL><Quality of life><Research><Research Personnel><Research Resources><Researchers><Resources><Sampling><Skin><Skin Diseases><Skin Diseases and Manifestations><Structure><Study Subject><Systems Biology><T Helper Factor><T-Cell Growth Factor 2><Therapeutic Intervention><Time><Topical Corticosteroids><Translating><United States National Institutes of Health><Viral Diseases><Virus Diseases><Work><allergic dermatitis><allergic eczema><atopic triad><atopy><bacteria infection><bacterial disease><biobank><biologic><biorepository><chronic inflammatory skin><cutaneous barrier><cutaneous disease><cutaneous microbiome><data integrity><data management and coordinating center><data management center><dermal barrier><dermal disease><dermal disorder><dermal microbiome><design><designing><developmental><dysbacteriosis><dysbiosis><dysbiotic><epidermal barrier><epidermal microbiome><evidence base><follower of religion Jewish><host response><immune system response><immunoresponse><intervention research><intervention therapy><interventional research><interventional strategy><interventional study><interventions research><lipidomics><lymphocyte activating factor><microbial><microbial imbalance><microbiome><microbiome transplant><microbiome transplantation><microbiota transplant><microbiota transplantation><new approaches><novel><novel approaches><novel strategies><novel strategy><operation><operations><organizational structure><pathophysiology><pathway><programs><response><response to therapy><response to treatment><rho><safety study><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><skin barrier><skin biome><skin disorder><skin microbiome><systemic inflammation><systemic inflammatory response><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic response><therapy response><transcriptomics><treatment response><treatment responsiveness><viral infection><virus infection><virus-induced disease>